GLOBAL ANTITHROMBOTIC DRUGS MARKET FORECAST 2018-2026
KEY FINDINGS
Globally, there has been a surge in the knee and hip replacement surgeries. Also, the NOACS are gaining increased adoption. Propelled by these factors, the global Antithrombotic drugs market is anticipated to evolve further at a CAGR of 6.83% over the forecast period of 2018-2026.
MARKET INSIGHTS
The antithrombotic drug market is segmented on the basis of anticoagulants, antiplatelet and thrombin inhibitors. Over the coming years, factors like rising prevalence of coagulation disorders and healthcare and related industries are expected to grow continuously, which is anticipated to provide tremendous scope for the market to expand. However, issues like patent expiration and lack of NOACS antidotes in the market are threatening the market progress.
REGIONAL INSIGHTS
Regionally, the global antithrombotic drugs market is segmented into Asia-Pacific, Europe, North America and rest of the world. By the end of the forecast period, North America is anticipated to dominate this market. Warfarin is a popular oral anticoagulant in this region. But the fastest growth is expected from the Asia-Pacific market due to improving healthcare scenario in this region.
COMPETITIVE INSIGHTS
Some of the leading market players dealing in antithrombotic drugs market include Abbot Laboratories, Armetheon Inc, Baxter International, Bayer, Boehringer Ingelheim Gmbh, Bristol-Myers Squibb Co, Csl Behring, Daiichi Sankyo Co. Ltd, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Novartis, Pfizer, and Sanofi.
Globally, there has been a surge in the knee and hip replacement surgeries. Also, the NOACS are gaining increased adoption. Propelled by these factors, the global Antithrombotic drugs market is anticipated to evolve further at a CAGR of 6.83% over the forecast period of 2018-2026.
MARKET INSIGHTS
The antithrombotic drug market is segmented on the basis of anticoagulants, antiplatelet and thrombin inhibitors. Over the coming years, factors like rising prevalence of coagulation disorders and healthcare and related industries are expected to grow continuously, which is anticipated to provide tremendous scope for the market to expand. However, issues like patent expiration and lack of NOACS antidotes in the market are threatening the market progress.
REGIONAL INSIGHTS
Regionally, the global antithrombotic drugs market is segmented into Asia-Pacific, Europe, North America and rest of the world. By the end of the forecast period, North America is anticipated to dominate this market. Warfarin is a popular oral anticoagulant in this region. But the fastest growth is expected from the Asia-Pacific market due to improving healthcare scenario in this region.
COMPETITIVE INSIGHTS
Some of the leading market players dealing in antithrombotic drugs market include Abbot Laboratories, Armetheon Inc, Baxter International, Bayer, Boehringer Ingelheim Gmbh, Bristol-Myers Squibb Co, Csl Behring, Daiichi Sankyo Co. Ltd, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Novartis, Pfizer, and Sanofi.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. ANTICOAGULANTS GENERATES THE HIGHEST REVENUE IN THE ANTITHROMBOTIC MARKET
3.2.2. ORAL ANTIPLATELETS ARE WIDELY USED
3.2.3. DIRECT FACTOR XA INHIBITORS ARE ANTICIPATED TO GROW SIGNIFICANTLY DURING THE FORECAST PERIOD
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. GROWING DEMAND FOR NOACS
4.1.2. SURGE IN HIP AND KNEE REPLACEMENT SURGERIES
4.1.3. HEALTHCARE POLICIES AND PROGRAMS BY THE GOVERNMENT
4.2. MARKET RESTRAINTS
4.2.1. SWELLING COST OF NOACS
4.2.2. GROWING AGING POPULATION IN SOME REGIONS
4.3. MARKET OPPORTUNITIES
4.3.1. GROWING PREVALENCE OF COAGULATION DISORDERS
4.3.2. HEALTHCARE AND RELATED INDUSTRIES ARE GROWING CONTINUOUSLY
4.4. MARKET CHALLENGES
4.4.1. LACK OF NOACS ANTIDOTES IN THE MARKET
4.4.2. PATENT EXPIRATION
5. MARKET SEGMENTATION
5.1. MARKET BY ANTITHROMBOTIC DRUGS TYPES
5.1.1. ANTICOAGULANTS
5.1.1.1. ANTICOAGULANTS BY DRUGS TYPE
5.1.1.1.1. LOW MOLECULAR WEIGHT HEPARIN
5.1.1.1.2. ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS)
5.1.1.2. ANTICOAGULANTS BY RAPID ONSET ANTICOAGULANT (ROA)
5.1.1.2.1. ORAL
5.1.1.2.2. INJECTABLES
5.1.1.3. ANTICOAGULANTS BY DRUG CLASS
5.1.1.3.1. FACTOR XA
5.1.1.3.2. DTIS
5.1.1.3.3. HEPARIN
5.1.1.3.4. VITAMIN K ANTAGONISTS
5.1.1.4. ANTICOAGULANTS BY APPLICATIONS
5.1.1.4.1. PE
5.1.1.4.2. DVT
5.1.1.4.3. AF
5.1.1.4.4. OTHER ANTICOAGULANTS APPLICATIONS
5.1.2. ANTIPLATELETS
5.1.2.1. ORAL ANTIPLATELETS
5.1.2.2. IV ANTIPLATELETS
5.1.3. THROMBIN INHIBITORS
5.1.3.1. DIRECT FACTOR XA INHIBITORS
5.1.3.2. DIRECT THROMBIN INHIBITORS
5.1.3.3. THROMBOLYTIC AGENTS
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCES ANALYSIS
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTES
6.1.3. BARGAINING POWER OF BUYERS
6.1.4. BARGAINING POWER OF SUPPLIERS
6.1.5. THREAT OF RIVALRY
6.2. PATENT ANALYSIS
6.3. MARKET TRENDS
6.3.1. STRATEGIC ALLIANCE
6.3.2. INCREASING FOCUS TOWARD EMERGING ECONOMIES
6.4. KEY DRUGS IN ANTITHROMBIC DRUGS MARKET
6.5. KEY BUYING CRITERIA
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. THE UNITED STATES
7.1.2. CANADA
7.2. EUROPE
7.2.1. THE UNITED KINGDOM
7.2.2. FRANCE
7.2.3. GERMANY
7.2.4. SPAIN
7.2.5. ITALY
7.2.6. REST OF EUROPE
7.3. ASIA PACIFIC
7.3.1. INDIA
7.3.2. CHINA
7.3.3. JAPAN
7.3.4. SOUTH KOREA
7.3.5. REST OF APAC
7.4. REST OF WORLD
7.4.1. MIDDLE EAST AND AFRICA (MEA)
7.4.2. LATIN AMERICA
8. COMPANY PROFILES
8.1. ABBOT LABORATORIES
8.1.1. COMPANY OVERVIEW
8.1.2. PRODUCT PORTFOLIO
8.1.3. SCOT ANALYSIS
8.1.4. STRATEGIC INITIATIVES
8.2. ARMETHEON INC.
8.2.1. COMPANY OVERVIEW
8.2.2. PRODUCT PORTFOLIO
8.2.3. STRATEGIC INITIATIVES
8.3. BAXTER INTERNATIONAL
8.3.1. COMPANY OVERVIEW
8.3.2. PRODUCT PORTFOLIO
8.3.3. STRATEGIC INITIATIVES
8.4. BAYER
8.4.1. COMPANY OVERVIEW
8.4.2. PRODUCT PORTFOLIO
8.4.3. SCOT ANALYSIS
8.4.4. STRATEGIC INITIATIVES
8.5. BOEHRINGER INGELHEIM GMBH
8.5.1. COMPANY OVERVIEW
8.5.2. PRODUCT PORTFOLIO
8.5.3. SCOT ANALYSIS
8.5.4. STRATEGIC INITIATIVES
8.6. BRISTOL-MYERS SQUIBB CO.
8.6.1. COMPANY OVERVIEW
8.6.2. PRODUCT PORTFOLIO
8.6.3. SCOT ANALYSIS
8.6.4. STRATEGIC INITIATIVES
8.7. CSL BEHRING
8.7.1. COMPANY OVERVIEW
8.7.2. PRODUCT PORTFOLIO
8.7.3. STRATEGIC INITIATIVES
8.8. DAIICHI SANKYO CO. LTD.
8.8.1. COMPANY OVERVIEW
8.8.2. PRODUCT PORTFOLIO
8.8.3. STRATEGIC INITIATIVES
8.9. ELI LILLY AND COMPANY
8.9.1. COMPANY OVERVIEW
8.9.2. PRODUCT PORTFOLIO
8.9.3. SCOT ANALYSIS
8.9.4. STRATEGIC INITIATIVES
8.10. F. HOFFMANN-LA ROCHE LTD
8.10.1. COMPANY OVERVIEW
8.10.2. PRODUCT PORTFOLIO:
8.10.3. SCOT ANALYSIS
8.10.4. STRATEGIC INITIATIVES
8.11. GLAXOSMITHKLINE
8.11.1. COMPANY OVERVIEW
8.11.2. PRODUCT PORTFOLIO
8.11.3. SCOT ANALYSIS
8.12. JOHNSON & JOHNSON
8.12.1. COMPANY OVERVIEW
8.12.2. PRODUCT PORTFOLIO
8.12.3. SWOT ANALYSIS
8.12.4. STRATEGIC INITIATIVES
8.13. MERCK & CO
8.13.1. COMPANY OVERVIEW
8.13.2. PRODUCT PORTFOLIO
8.13.3. SCOT ANALYSIS
8.13.4. STRATEGIC INITIATIVES
8.14. NOVARTIS
8.14.1. COMPANY OVERVIEW
8.14.2. PRODUCTS PORTFOLIO
8.14.3. SCOT ANALYSIS
8.14.4. STRATEGIC INITIATIVES
8.15. PFIZER
8.15.1. COMPANY OVERVIEW
8.15.2. PRODUCT PORTFOLIO
8.15.3. SCOT ANALYSIS
8.15.4. STRATEGIC INITIATIVES
8.16. SANOFI
8.16.1. COMPANY OVERVIEW
8.16.2. PRODUCT PORTFOLIO
8.16.3. SCOT ANALYSIS
8.16.4. STRATEGIC INITIATIVES
TABLE LIST
TABLE 1 GLOBAL ANTITHROMBOTIC DRUGS MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 2 INDIAN GOVERNMENT INITIATIVES IN THE HEALTHCARE SECTOR
TABLE 3 GLOBAL ANTITHROMBOTIC DRUGS MARKET BY TYPES 2018-2026 ($ MILLION)
TABLE 4 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTICOAGULANTS BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 5 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTICOAGULANTS BY DRUGS TYPE 2018-2026 ($ MILLION)
TABLE 6 GLOBAL ANTICOAGULANTS MARKET IN LOW MOLECULAR WEIGHT HEPARIN BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 7 LOVENOX DRUG BRAND
TABLE 8 GLOBAL ANTICOAGULANTS MARKET IN LOW ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS) BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 9 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTICOAGULANTS BY ROA 2018-2026 ($ MILLION)
TABLE 10 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTICOAGULANTS BY DRUG CLASS 2018-2026 ($ MILLION)
TABLE 11 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTICOAGULANTS BY APPLICATIONS 2018-2026 ($ MILLION)
TABLE 12 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTIPLATELETS BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 13 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTIPLATELETS BY TYPES 2018-2026 ($ MILLION)
TABLE 14 GLOBAL ANTIPLATELETS MARKET IN ORAL ANTIPLATELETS BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 15 GLOBAL ANTIPLATELETS MARKET IN IV ANTIPLATELETS BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 16 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN THROMBIN INHIBITORS BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 17 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN THROMBIN INHIBITORS BY TYPES 2018-2026 ($ MILLION)
TABLE 18 NUMBER OF PATENTS ON ANTITHROMBOTICS AND ANTICOAGULANTS BY VARIOUS COMPANIES 2011-2016
TABLE 19 NUMBERS OF PATENTS ON ANTICOAGULANTS BY VARIOUS COMPANIES 2011-2016
TABLE 20 NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET BY COUNTRIES 2018-202 ($ MILLION)
TABLE 21 EUROPE ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
TABLE 22 ASIA PACIFIC ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
TABLE 23 REST OF WORLD ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. ANTICOAGULANTS GENERATES THE HIGHEST REVENUE IN THE ANTITHROMBOTIC MARKET
3.2.2. ORAL ANTIPLATELETS ARE WIDELY USED
3.2.3. DIRECT FACTOR XA INHIBITORS ARE ANTICIPATED TO GROW SIGNIFICANTLY DURING THE FORECAST PERIOD
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. GROWING DEMAND FOR NOACS
4.1.2. SURGE IN HIP AND KNEE REPLACEMENT SURGERIES
4.1.3. HEALTHCARE POLICIES AND PROGRAMS BY THE GOVERNMENT
4.2. MARKET RESTRAINTS
4.2.1. SWELLING COST OF NOACS
4.2.2. GROWING AGING POPULATION IN SOME REGIONS
4.3. MARKET OPPORTUNITIES
4.3.1. GROWING PREVALENCE OF COAGULATION DISORDERS
4.3.2. HEALTHCARE AND RELATED INDUSTRIES ARE GROWING CONTINUOUSLY
4.4. MARKET CHALLENGES
4.4.1. LACK OF NOACS ANTIDOTES IN THE MARKET
4.4.2. PATENT EXPIRATION
5. MARKET SEGMENTATION
5.1. MARKET BY ANTITHROMBOTIC DRUGS TYPES
5.1.1. ANTICOAGULANTS
5.1.1.1. ANTICOAGULANTS BY DRUGS TYPE
5.1.1.1.1. LOW MOLECULAR WEIGHT HEPARIN
5.1.1.1.2. ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS)
5.1.1.2. ANTICOAGULANTS BY RAPID ONSET ANTICOAGULANT (ROA)
5.1.1.2.1. ORAL
5.1.1.2.2. INJECTABLES
5.1.1.3. ANTICOAGULANTS BY DRUG CLASS
5.1.1.3.1. FACTOR XA
5.1.1.3.2. DTIS
5.1.1.3.3. HEPARIN
5.1.1.3.4. VITAMIN K ANTAGONISTS
5.1.1.4. ANTICOAGULANTS BY APPLICATIONS
5.1.1.4.1. PE
5.1.1.4.2. DVT
5.1.1.4.3. AF
5.1.1.4.4. OTHER ANTICOAGULANTS APPLICATIONS
5.1.2. ANTIPLATELETS
5.1.2.1. ORAL ANTIPLATELETS
5.1.2.2. IV ANTIPLATELETS
5.1.3. THROMBIN INHIBITORS
5.1.3.1. DIRECT FACTOR XA INHIBITORS
5.1.3.2. DIRECT THROMBIN INHIBITORS
5.1.3.3. THROMBOLYTIC AGENTS
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCES ANALYSIS
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTES
6.1.3. BARGAINING POWER OF BUYERS
6.1.4. BARGAINING POWER OF SUPPLIERS
6.1.5. THREAT OF RIVALRY
6.2. PATENT ANALYSIS
6.3. MARKET TRENDS
6.3.1. STRATEGIC ALLIANCE
6.3.2. INCREASING FOCUS TOWARD EMERGING ECONOMIES
6.4. KEY DRUGS IN ANTITHROMBIC DRUGS MARKET
6.5. KEY BUYING CRITERIA
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. THE UNITED STATES
7.1.2. CANADA
7.2. EUROPE
7.2.1. THE UNITED KINGDOM
7.2.2. FRANCE
7.2.3. GERMANY
7.2.4. SPAIN
7.2.5. ITALY
7.2.6. REST OF EUROPE
7.3. ASIA PACIFIC
7.3.1. INDIA
7.3.2. CHINA
7.3.3. JAPAN
7.3.4. SOUTH KOREA
7.3.5. REST OF APAC
7.4. REST OF WORLD
7.4.1. MIDDLE EAST AND AFRICA (MEA)
7.4.2. LATIN AMERICA
8. COMPANY PROFILES
8.1. ABBOT LABORATORIES
8.1.1. COMPANY OVERVIEW
8.1.2. PRODUCT PORTFOLIO
8.1.3. SCOT ANALYSIS
8.1.4. STRATEGIC INITIATIVES
8.2. ARMETHEON INC.
8.2.1. COMPANY OVERVIEW
8.2.2. PRODUCT PORTFOLIO
8.2.3. STRATEGIC INITIATIVES
8.3. BAXTER INTERNATIONAL
8.3.1. COMPANY OVERVIEW
8.3.2. PRODUCT PORTFOLIO
8.3.3. STRATEGIC INITIATIVES
8.4. BAYER
8.4.1. COMPANY OVERVIEW
8.4.2. PRODUCT PORTFOLIO
8.4.3. SCOT ANALYSIS
8.4.4. STRATEGIC INITIATIVES
8.5. BOEHRINGER INGELHEIM GMBH
8.5.1. COMPANY OVERVIEW
8.5.2. PRODUCT PORTFOLIO
8.5.3. SCOT ANALYSIS
8.5.4. STRATEGIC INITIATIVES
8.6. BRISTOL-MYERS SQUIBB CO.
8.6.1. COMPANY OVERVIEW
8.6.2. PRODUCT PORTFOLIO
8.6.3. SCOT ANALYSIS
8.6.4. STRATEGIC INITIATIVES
8.7. CSL BEHRING
8.7.1. COMPANY OVERVIEW
8.7.2. PRODUCT PORTFOLIO
8.7.3. STRATEGIC INITIATIVES
8.8. DAIICHI SANKYO CO. LTD.
8.8.1. COMPANY OVERVIEW
8.8.2. PRODUCT PORTFOLIO
8.8.3. STRATEGIC INITIATIVES
8.9. ELI LILLY AND COMPANY
8.9.1. COMPANY OVERVIEW
8.9.2. PRODUCT PORTFOLIO
8.9.3. SCOT ANALYSIS
8.9.4. STRATEGIC INITIATIVES
8.10. F. HOFFMANN-LA ROCHE LTD
8.10.1. COMPANY OVERVIEW
8.10.2. PRODUCT PORTFOLIO:
8.10.3. SCOT ANALYSIS
8.10.4. STRATEGIC INITIATIVES
8.11. GLAXOSMITHKLINE
8.11.1. COMPANY OVERVIEW
8.11.2. PRODUCT PORTFOLIO
8.11.3. SCOT ANALYSIS
8.12. JOHNSON & JOHNSON
8.12.1. COMPANY OVERVIEW
8.12.2. PRODUCT PORTFOLIO
8.12.3. SWOT ANALYSIS
8.12.4. STRATEGIC INITIATIVES
8.13. MERCK & CO
8.13.1. COMPANY OVERVIEW
8.13.2. PRODUCT PORTFOLIO
8.13.3. SCOT ANALYSIS
8.13.4. STRATEGIC INITIATIVES
8.14. NOVARTIS
8.14.1. COMPANY OVERVIEW
8.14.2. PRODUCTS PORTFOLIO
8.14.3. SCOT ANALYSIS
8.14.4. STRATEGIC INITIATIVES
8.15. PFIZER
8.15.1. COMPANY OVERVIEW
8.15.2. PRODUCT PORTFOLIO
8.15.3. SCOT ANALYSIS
8.15.4. STRATEGIC INITIATIVES
8.16. SANOFI
8.16.1. COMPANY OVERVIEW
8.16.2. PRODUCT PORTFOLIO
8.16.3. SCOT ANALYSIS
8.16.4. STRATEGIC INITIATIVES
TABLE LIST
TABLE 1 GLOBAL ANTITHROMBOTIC DRUGS MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 2 INDIAN GOVERNMENT INITIATIVES IN THE HEALTHCARE SECTOR
TABLE 3 GLOBAL ANTITHROMBOTIC DRUGS MARKET BY TYPES 2018-2026 ($ MILLION)
TABLE 4 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTICOAGULANTS BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 5 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTICOAGULANTS BY DRUGS TYPE 2018-2026 ($ MILLION)
TABLE 6 GLOBAL ANTICOAGULANTS MARKET IN LOW MOLECULAR WEIGHT HEPARIN BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 7 LOVENOX DRUG BRAND
TABLE 8 GLOBAL ANTICOAGULANTS MARKET IN LOW ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS) BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 9 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTICOAGULANTS BY ROA 2018-2026 ($ MILLION)
TABLE 10 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTICOAGULANTS BY DRUG CLASS 2018-2026 ($ MILLION)
TABLE 11 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTICOAGULANTS BY APPLICATIONS 2018-2026 ($ MILLION)
TABLE 12 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTIPLATELETS BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 13 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTIPLATELETS BY TYPES 2018-2026 ($ MILLION)
TABLE 14 GLOBAL ANTIPLATELETS MARKET IN ORAL ANTIPLATELETS BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 15 GLOBAL ANTIPLATELETS MARKET IN IV ANTIPLATELETS BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 16 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN THROMBIN INHIBITORS BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 17 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN THROMBIN INHIBITORS BY TYPES 2018-2026 ($ MILLION)
TABLE 18 NUMBER OF PATENTS ON ANTITHROMBOTICS AND ANTICOAGULANTS BY VARIOUS COMPANIES 2011-2016
TABLE 19 NUMBERS OF PATENTS ON ANTICOAGULANTS BY VARIOUS COMPANIES 2011-2016
TABLE 20 NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET BY COUNTRIES 2018-202 ($ MILLION)
TABLE 21 EUROPE ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
TABLE 22 ASIA PACIFIC ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
TABLE 23 REST OF WORLD ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURES LIST
FIGURE 1 GLOBAL ANTITHROMBOTIC DRUGS MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
FIGURE 2 INDUSTRY IN THE WORLD IS RAPIDLY GROWING (%)
FIGURE 3 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTICOAGULANTS 2018-2026 ($ MILLION)
FIGURE 4 BLOOD COAGULATION PROCESS
FIGURE 5 GLOBAL ANTICOAGULANTS MARKET IN ORAL 2018-2026 ($ MILLION)
FIGURE 6 GLOBAL ANTICOAGULANTS MARKET IN INJECTABLES 2018-2026 ($ MILLION)
FIGURE 7 GLOBAL ANTICOAGULANTS MARKET IN FACTOR XA 2018-2026 ($ MILLION)
FIGURE 8 GLOBAL ANTICOAGULANTS MARKET IN DTIS 2018-2026 ($ MILLION)
FIGURE 9 GLOBAL ANTICOAGULANTS MARKET IN HEPARIN 2018-2026 ($ MILLION)
FIGURE 10 GLOBAL ANTICOAGULANTS MARKET IN VITAMIN K ANTAGONISTS 2018-2026 ($ MILLION)
FIGURE 11 GLOBAL ANTICOAGULANTS MARKET IN PE 2018-2026 ($ MILLION)
FIGURE 12 GLOBAL ANTICOAGULANTS MARKET IN DVT 2018-2026 ($ MILLION)
FIGURE 13 GLOBAL ANTICOAGULANTS MARKET IN AF 2018-2026 ($ MILLION)
FIGURE 14 GLOBAL ANTICOAGULANTS MARKET IN OTHER ANTICOAGULANTS APPLICATIONS 2018-2026 ($ MILLION)
FIGURE 15 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTIPLATELETS 2018-2026 ($ MILLION)
FIGURE 16 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN THROMBIN INHIBITORS 2018-2026 ($ MILLION)
FIGURE 17 GLOBAL THROMBIN INHIBITORS MARKET IN DIRECT FACTOR XA INHIBITORS 2018-2026 ($ MILLION)
FIGURE 18 GLOBAL THROMBIN INHIBITORS MARKET IN DIRECT THROMBIN INHIBITORS 2018-2026 ($ MILLION)
FIGURE 19 GLOBAL THROMBIN INHIBITORS MARKET IN THROMBOLYTIC AGENTS2018-2026 ($ MILLION)
FIGURE 20 GLOBAL ANTITHROMBOTIC DRUGS MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
FIGURE 21 THE UNITED STATES ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 22 CANADA ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 23 THE UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 24 FRANCE ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 25 GERMANY ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 26 SPAIN ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 27 ITALY ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 28 REST OF EUROPE ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 29 INDIA ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 30 CHINA ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 31 JAPAN ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 32 SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 33 REST OF APAC ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 34 MIDDLE EAST AND AFRICA ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 35 LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
COMPANIES MENTIONED
1. ABBOT LABORATORIES
2. ARMETHEON INC.
3. BAXTER INTERNATIONAL
4. BAYER
5. BOEHRINGER INGELHEIM GMBH
6. BRISTOL-MYERS SQUIBB CO.
7. CSL BEHRING
8. DAIICHI SANKYO CO. LTD.
9. ELI LILLY AND COMPANY
10. F. HOFFMANN-LA ROCHE LTD
11. GLAXOSMITHKLINE
12. JOHNSON & JOHNSON
13. MERCK & CO
14. NOVARTIS
15. PFIZER
16. SANOFI
FIGURE 1 GLOBAL ANTITHROMBOTIC DRUGS MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
FIGURE 2 INDUSTRY IN THE WORLD IS RAPIDLY GROWING (%)
FIGURE 3 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTICOAGULANTS 2018-2026 ($ MILLION)
FIGURE 4 BLOOD COAGULATION PROCESS
FIGURE 5 GLOBAL ANTICOAGULANTS MARKET IN ORAL 2018-2026 ($ MILLION)
FIGURE 6 GLOBAL ANTICOAGULANTS MARKET IN INJECTABLES 2018-2026 ($ MILLION)
FIGURE 7 GLOBAL ANTICOAGULANTS MARKET IN FACTOR XA 2018-2026 ($ MILLION)
FIGURE 8 GLOBAL ANTICOAGULANTS MARKET IN DTIS 2018-2026 ($ MILLION)
FIGURE 9 GLOBAL ANTICOAGULANTS MARKET IN HEPARIN 2018-2026 ($ MILLION)
FIGURE 10 GLOBAL ANTICOAGULANTS MARKET IN VITAMIN K ANTAGONISTS 2018-2026 ($ MILLION)
FIGURE 11 GLOBAL ANTICOAGULANTS MARKET IN PE 2018-2026 ($ MILLION)
FIGURE 12 GLOBAL ANTICOAGULANTS MARKET IN DVT 2018-2026 ($ MILLION)
FIGURE 13 GLOBAL ANTICOAGULANTS MARKET IN AF 2018-2026 ($ MILLION)
FIGURE 14 GLOBAL ANTICOAGULANTS MARKET IN OTHER ANTICOAGULANTS APPLICATIONS 2018-2026 ($ MILLION)
FIGURE 15 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTIPLATELETS 2018-2026 ($ MILLION)
FIGURE 16 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN THROMBIN INHIBITORS 2018-2026 ($ MILLION)
FIGURE 17 GLOBAL THROMBIN INHIBITORS MARKET IN DIRECT FACTOR XA INHIBITORS 2018-2026 ($ MILLION)
FIGURE 18 GLOBAL THROMBIN INHIBITORS MARKET IN DIRECT THROMBIN INHIBITORS 2018-2026 ($ MILLION)
FIGURE 19 GLOBAL THROMBIN INHIBITORS MARKET IN THROMBOLYTIC AGENTS2018-2026 ($ MILLION)
FIGURE 20 GLOBAL ANTITHROMBOTIC DRUGS MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
FIGURE 21 THE UNITED STATES ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 22 CANADA ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 23 THE UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 24 FRANCE ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 25 GERMANY ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 26 SPAIN ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 27 ITALY ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 28 REST OF EUROPE ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 29 INDIA ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 30 CHINA ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 31 JAPAN ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 32 SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 33 REST OF APAC ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 34 MIDDLE EAST AND AFRICA ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
FIGURE 35 LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET 2018-202 ($ MILLION)
COMPANIES MENTIONED
1. ABBOT LABORATORIES
2. ARMETHEON INC.
3. BAXTER INTERNATIONAL
4. BAYER
5. BOEHRINGER INGELHEIM GMBH
6. BRISTOL-MYERS SQUIBB CO.
7. CSL BEHRING
8. DAIICHI SANKYO CO. LTD.
9. ELI LILLY AND COMPANY
10. F. HOFFMANN-LA ROCHE LTD
11. GLAXOSMITHKLINE
12. JOHNSON & JOHNSON
13. MERCK & CO
14. NOVARTIS
15. PFIZER
16. SANOFI
